| Q22242399 | A review of the association between obesity and cognitive function across the lifespan: implications for novel approaches to prevention and treatment |
| Q36776169 | Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease: an epidemiological perspective |
| Q37250859 | Adiposity, type 2 diabetes, and Alzheimer's disease |
| Q46808245 | Aging-related correlation of insulin-degrading enzyme with gamma-secretase-generated products involving insulin and glucose levels in transgenic mice |
| Q24300365 | Alternative translation initiation generates a novel isoform of insulin-degrading enzyme targeted to mitochondria |
| Q37212345 | Alzheimer's disease and type 2 diabetes: exploring the association to obesity and tyrosine hydroxylase |
| Q35801866 | Cardiovascular risk factors and Alzheimer's disease |
| Q52009127 | Cerebrospinal fluid levels of insulin in patients with Alzheimer's disease. |
| Q101237460 | Chia seeds as a potential cognitive booster in the APP23 Alzheimer's disease model |
| Q40506191 | Comorbid Depression and Diabetes as a Risk for Mild Cognitive Impairment and Alzheimer's Disease in Elderly Mexican Americans |
| Q34361375 | Diabetes, related conditions, and dementia. |
| Q24250162 | Effect of the treatment of Type II diabetes mellitus on the development of cognitive impairment and dementia |
| Q33623924 | Estrogen: a master regulator of bioenergetic systems in the brain and body |
| Q37686190 | Follow-up for Alzheimer patients: European Alzheimer Disease Consortium position paper |
| Q47556291 | Insulin Resistance is Associated with Cognitive Decline Among Older Koreans with Normal Baseline Cognitive Function: A Prospective Community-Based Cohort Study. |
| Q39272444 | Insulin and IGF-I prevent brain atrophy and DNA loss in diabetes |
| Q34105422 | Insulin receptors and insulin action in the brain: review and clinical implications |
| Q24683214 | Insulin-degrading enzyme regulates the levels of insulin, amyloid beta-protein, and the beta-amyloid precursor protein intracellular domain in vivo |
| Q38938961 | Is Alzheimer's disease a Type 3 Diabetes? A critical appraisal |
| Q36860616 | Is Glucagon-like peptide-1, an agent treating diabetes, a new hope for Alzheimer's disease? |
| Q41767433 | L-arginine and Alzheimer's disease. |
| Q38176522 | Mechanisms of action of brain insulin against neurodegenerative diseases. |
| Q33607450 | Menopause and estrogen deficiency as a risk factor in dementing illness: hypothesis on the biological basis. |
| Q26783344 | Molecular and biochemical trajectories from diabetes to Alzheimer's disease: A critical appraisal |
| Q50932512 | Multiple functions of insulin-degrading enzyme: a metabolic crosslight? |
| Q47688481 | Neurocognitive performances of visuospatial attention and the correlations with metabolic and inflammatory biomarkers in adults with obesity |
| Q38105048 | Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions? |
| Q35791191 | Neurodegenerative disorders associated with diabetes mellitus |
| Q60168083 | Neuroenergetics of traumatic brain injury |
| Q35041925 | Obesity, insulin resistance, and Alzheimer's disease |
| Q37215869 | PPARgamma agonists as therapeutics for the treatment of Alzheimer's disease |
| Q35097358 | Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein |
| Q30235369 | Pathophysiologic relationship between Alzheimer's disease, cerebrovascular disease, and cardiovascular risk: A review and synthesis |
| Q47593479 | Perspectives of Alzheimer's disease treatments |
| Q53396257 | Pharmacognostical Sources of Popular Medicine To Treat Alzheimer's Disease. |
| Q37729219 | Potential Neuroprotective Effects of Adiponectin in Alzheimer's Disease |
| Q38994712 | Relationship Between Obesity, Alzheimer's Disease, and Parkinson's Disease: an Astrocentric View |
| Q35666080 | Role of hydrogen peroxide in the aetiology of Alzheimer's disease: implications for treatment. |
| Q53229530 | Serum zinc, copper, insulin and lipids in Alzheimer's disease epsilon 4 apolipoprotein E allele carriers. |
| Q34155597 | Statin users without an APOE-epsilon4 allele have increased insulin resistance |
| Q38708062 | Tau deletion promotes brain insulin resistance |
| Q35327219 | The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease |
| Q34997212 | The PPAR-gamma Pro12Ala polymorphism and risk of cognitive impairment in a longitudinal study |
| Q36092439 | The effects of energy-rich diets on discrimination reversal learning and on BDNF in the hippocampus and prefrontal cortex of the rat. |
| Q28571907 | The effects of induced type-I diabetes on developmental regulation of insulin & insulin like growth factor-1 (IGF-1) receptors in the cerebellum of rat neonates |
| Q49158736 | The metabolism of plasma glucose and catecholamines in Alzheimer's disease |
| Q35017640 | The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment |
| Q37029352 | The role of peroxisome proliferator-activated receptor-gamma (PPARgamma) in Alzheimer's disease: therapeutic implications |
| Q48935013 | Traumatic brain injury and obesity induce persistent central insulin resistance |
| Q33362745 | Unraveling Alzheimer's: Making Sense of the Relationship between Diabetes and Alzheimer's Disease1 |
| Q53226580 | Vascular nitric oxide may lessen Alzheimer's risk. |